Henry Meds vs MEDVi vs Mochi Health (2026)

On tirzepatide, the order is Mochi Health↗ ($278) → Henry Meds↗ ($349) → MEDVi↗ ($399) — gaps of $71 and then $50 a month, a $1,452 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

§ Each record, condensed

The three records, one screen

Mochi Health: the record, condensed

On tirzepatide, the number that matters at Mochi Health is $278 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at Mochi Health is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

A required $79/month membership is part of the deal, and part of the figure above: $199 of medication plus $79 of platform equals the $278 that leaves your account. Judge the membership by what it includes, but compare on the total.

Context for that figure: it ranks #4 of 17 in the verified tirzepatide index — $63/month above the floor (NexLife↗, $215) — and sits $171 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $3,336.

Mochi Health’s semaglutide program bills $178 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Inside that $178 sits a mandatory $79-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $99, and it is not a price anyone can actually pay, because the membership cannot be declined.

To place the number: #8 of 20 verified programs, with the floor $45/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $171 a month. A year at this figure: $2,136 monthly-billed.

Operationally at Mochi Health: shipping included; commitment membership recurs monthly; cancellation cancel membership any time; recurs until cancelled; pharmacy named (company-owned compounding facility); states: most states; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Mochi Health page · visit Mochi Health ↗

Henry Meds: the record, condensed

Start with the load-bearing figure: $349 a month, all-in, is what Henry Meds charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $349 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #10 of 17 verified programs, with the floor $134/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $100 a month. A year at this figure: $4,188 monthly-billed.

On semaglutide, the number that matters at Henry Meds is $179 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Henry Meds is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $179 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #9 of 20 in the verified semaglutide index — $46/month above the floor (Oak Longevity, $133) — and sits $170 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,148.

Operationally at Henry Meds: shipping included; commitment none month-to-month; cancellation check terms before prepaying; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Henry Meds page · visit Henry Meds ↗

MEDVi: the record, condensed

MEDVi’s tirzepatide program bills $399 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $399 is the whole subscription, which makes MEDVi unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #14 of 17 in the verified tirzepatide index — $184/month above the floor (NexLife, $215) — and sits $50 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $4,788.

Start with the load-bearing figure: $299 a month, all-in, is what MEDVi charges for semaglutide at the 2.4 mg basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at MEDVi is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #18 of 20 verified programs, with the floor $166/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $50 a month. A year at this figure: $3,588 monthly-billed.

Operationally at MEDVi: shipping included; commitment 12-month plan for the lowest rate; cancellation 12-month plan applies to lowest rate; pharmacy not publicly named — ask in writing before paying; states: priced differently in CA/NC on some plans; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the MEDVi page · visit MEDVi ↗

§ The three-way read

Prices, gaps, and what sits inside them

Mochi Health holds the low ground at $278 — dose-flat, so that figure is a ceiling (its $79 membership already inside). Henry Meds follows at $349 (+$71/mo, $852/yr). MEDVi tops the trio at $399 (+$121/mo over the leader, $1,452/yr) — note its record’s watch-out below.

The semaglutide picture reshuffles nothing: Mochi Health $178 → Henry Meds $179 → MEDVi $299 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.

§ Category winners among the three

Who wins what

Cheapest month-to-month: Mochi Health ($278); cheapest 12-month path: Mochi Health ($3,336); simplest billing (no membership): Henry Meds and MEDVi; named-pharmacy transparency: Mochi Health; cheapest semaglutide of the three: Mochi Health ($178).

Every winner above is a computation, not a placement; the pairwise pages carry the full duels: Mochi Health vs Henry Meds · Mochi Health vs MEDVi · Henry Meds vs MEDVi.

§ Structure, three ways

Everything besides the three prices

Memberships: Mochi Health $79/mo (inside its figure); Henry Meds none; MEDVi none. Structures: Mochi Health dose-flat; Henry Meds dose-flat; MEDVi dose-flat. Pharmacies: Mochi Health named (company-owned compounding facility); Henry Meds not named; MEDVi not named. States: Mochi Health — most states; Henry Meds — most states; MEDVi — priced differently in CA/NC on some plans. Exit terms: Mochi Health — cancel membership any time; recurs until cancelled; Henry Meds — check terms before prepaying; MEDVi — 12-month plan applies to lowest rate.

The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: Mochi Health source-verified (2026-08-05); Henry Meds third-party reported (2026-08-05); MEDVi source-verified (2026-08-05).

The trio on semaglutide, across time

3 mo: Mochi Health $534 vs Henry Meds $537 vs MEDVi $897 6 mo: Mochi Health $1,068 vs Henry Meds $1,074 vs MEDVi $1,794 12 mo: Mochi Health $2,136 vs Henry Meds $2,148 vs MEDVi $3,588 — monthly-billed totals; prepaid paths where published appear on each provider page.

§ Twelve and twenty-four months

The trio, annualized

Mochi Health: $3,336/yr monthly-billed; Henry Meds: $4,188/yr monthly-billed; MEDVi: $4,788/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $2,904 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.

The elimination read

A three-way choice is really two eliminations, so run them in order. Eliminate MEDVi first unless it names its edge: at $399 it carries a $121/month premium over the floor of this trio — $1,452 a year, about 5.2 extra months of therapy at Mochi Health’s rate — and a premium that size must point at a specific line in its record (its particular program design) or it is decoration. Then interrogate Henry Meds’s middle ground: nothing structural — its case is purely situational; if that specific thing is on your personal ledger, the $71/month over the floor can be rational — if not, the middle is where budgets go to leak. What survives is Mochi Health at $278, which wins by default rather than by argument — exactly how a price index should crown things — subject to the two checks no ranking can run for you: your state at intake, and your prescriber on the medication itself.

The same trio on best published rate: Mochi Health $278 → Henry Meds $349 → MEDVi $399 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — Mochi Health $834, Henry Meds $1,047, MEDVi $1,197; 6 months — Mochi Health $1,668, Henry Meds $2,094, MEDVi $2,394. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.

The record-quality read, scored on the five checkable disclosures this index tracks (maintenance price, named pharmacy, published states, published cancellation terms, source-verified capture): Mochi Health 5/5, Henry Meds 3/5, MEDVi 4/5. Mochi Health discloses the most and Henry Meds the least, and in this market disclosure predicts disclosure — the axis where a program goes quiet is reliably where its checkout surprises live. Where the trio actually splits: pharmacy named: Mochi Health yes, Henry Meds and MEDVi no — each split is a written intake question before any card number. Scores recompute from the public records like everything else here.

Read as a decision: start from Mochi Health and make the other two argue upward. Henry Meds’s case is its structure; MEDVi’s case must be worth $1,452 a year in named features — the honest unit being months of medication (5.2 of them at the floor rate). The pairwise pages above hold each argument in full, and the calculator holds your version of it.